Clinical Status of Inhaled Nitric Oxide Treatment in Infants with Persistent Pulmonary Hypertension of the Newborn in Korea: Post-Marketing Surveillance Results
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Inhaled nitric oxide (iNO) is a potent selective pulmonary vasodilator and an important treatment for newborn infants with hypoxic respiratory failure due to persistent pulmonary hypertension of the newborn (PPHN). The Ministry of Food and Drug Safety of Korea first approved iNO in 2009 for use as a new drug to treat hypoxic respiratory failure with PPHN. A post-marketing surveillance study (PMSS) was conducted to assess the effectiveness and safety of the iNO treatment. We evaluated the clinical status of the iNO treatment currently available in Korea by using the PMSS data. Methods: We retrospectively reviewed the PMSS data from 22 hospitals in Korea from October 2014 to September 2018. Altogether, 97 infants were enrolled and divided into early response (ER), delayed response (DR), no response (NR), and death groups according to their response to the iNO treatment. Results: The ER group included 52 infants (53.6%); DR group, 33 (34.0%); NR group, seven (7.2%); and death group, five (5.2%). The iNO treatment was initiated within 14 days after birth at a concentration of 20 ppm. The median treatment duration was 91.5 hours (69.0 to 134.3) in all the infants. Of the infants, 43 (44.3%) received the treatment for >96 hours. Fifty-one infants (52.6%) needed >20 ppm of iNO, and 10 (10.5%) needed a maximum of 80 ppm of iNO. None of the infants had hypermethemoglobinemia or an alarm report of NO2. Conclusion: Korean neonatologists reported that a large proportion of the infants with PPHN showed improvement in oxygenation after treatment with the approved iNO. These infants received relatively longer durations and higher concentrations of the iNO treatment than the current recommendations, without any side and adverse effect.
Abstract
Purpose: Inhaled nitric oxide (iNO) is a potent selective pulmonary vasodilator and an important treatment for newborn infants with hypoxic respiratory failure due to persistent pulmonary hypertension of the newborn (PPHN). The Ministry of Food and Drug Safety of Korea first approved iNO in 2009 for use as a new drug to treat hypoxic respiratory failure with PPHN. A post-marketing surveillance study (PMSS) was conducted to assess the effectiveness and safety of the iNO treatment. We evaluated the clinical status of the iNO treatment currently available in Korea by using the PMSS data. Methods: We retrospectively reviewed the PMSS data from 22 hospitals in Korea from October 2014 to September 2018. Altogether, 97 infants were enrolled and divided into early response (ER), delayed response (DR), no response (NR), and death groups according to their response to the iNO treatment. Results: The ER group included 52 infants (53.6%); DR group, 33 (34.0%); NR group, seven (7.2%); and death group, five (5.2%). The iNO treatment was initiated within 14 days after birth at a concentration of 20 ppm. The median treatment duration was 91.5 hours (69.0 to 134.3) in all the infants. Of the infants, 43 (44.3%) received the treatment for >96 hours. Fifty-one infants (52.6%) needed >20 ppm of iNO, and 10 (10.5%) needed a maximum of 80 ppm of iNO. None of the infants had hypermethemoglobinemia or an alarm report of NO2. Conclusion: Korean neonatologists reported that a large proportion of the infants with PPHN showed improvement in oxygenation after treatment with the approved iNO. These infants received relatively longer durations and higher concentrations of the iNO treatment than the current recommendations, without any side and adverse effect.
참고문헌 (15)
- Pepke-Zaba J, "Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension", Lancet, 338, pp.1173~1174 (1991)
- Roberts JD, "Inhaled nitric oxide in persistent pulmonary hypertension of the newborn", Lancet, 340, pp.818~819 (1992)
- Kinsella JP, "Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn", Lancet, 340, pp.819~820 (1992)
- Kinsella JP, "Inhaled nitric oxide in the term newborn", Early Hum Dev, 84, pp.709~716 (2008)
- DiBlasi RM, "Evidence-based clinical practice guideline : inhaled nitric oxide for neonates with acute hypoxic respiratory failure", Respir Care, 55, pp.1717~1745 (2010)
- Peliowski A, "Inhaled nitric oxide use in newborns", Paediatr Child Health, 17, pp.95~100 (2012)
- Neonatal Inhaled Nitric Oxide Study Group, "Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure", N Engl J Med, 336, pp.597~604 (1997)
- Clark RH, "Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group", N Engl J Med, 342, pp.469~474 (2000)
- Barrington KJ, "Nitric oxide for respiratory failure in infants born at or near term", Cochrane Database Syst Rev, 1, pp.CD000399~ (2017)
- 이은희, "신생아 지속 폐동맥 고혈압에서 흡입 일산화질소 치료의 임상적 적용", Neonatal medicine, 22(2), pp.61~70 (2015), 대한신생아학회
- Davidson D, "Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO", PPHN Study Group, 1998, pp.101(3 Pt 1), 325~334
- Rhine WD, "An analysis of time to improvement in oxygenation in Japanese preterm and late preterm or term neonates with hypoxic respiratory failure and pulmonary hypertension", Clin Ther, 41, pp.910~919 (2019)
- Goldman AP, "Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn", Pediatrics, 98(4Pt 1), pp.706~713 (1996)
- Guthrie SO, "Initial dosing of inhaled nitric oxide in infants with hypoxic respiratory failure", J Perinatol, 24, pp.290~294 (2004)
- 안소윤, "신생아 지속성 폐동맥 고혈압증에서 흡입 일산화질소 치료 임상 경과와 부작용", Neonatal medicine, 22(2), pp.71~77 (2015), 대한신생아학회